Abstract. MicroRNAs (miRNAs) are vital regulators of non-small cell lung cancer (NSCLC) development and tumorigenesis. The aim of the present study was to explore the role of miRNA (miR)-1296 expression in NSCLC. The expression of miR-1296 was detected by reverse transcription-quantitative PCR in NSCLC tissues and matched normal tissues. The association of miR-1296 expression with clini-
Introduction
Lung cancer is one of the most rapidly growing types of cancer and exhibits a high cancer-associated morbidity rate worldwide (1) . Non-small cell lung cancer (NSCLC) accounts for ~80% of lung cancer cases (2) . Treatment methods, including surgery, radiotherapy, chemotherapy and molecular targeted therapy, have improved the overall survival rate, but prognosis for patients diagnosed at an advanced stage remains poor (3, 4) . Therefore, it is urgent to investigate novel biomarkers for diagnosis and prediction of prognosis for patients with NSCLC.
MicroRNAs (miRNAs) are a class of small non-coding RNAs involved in post-transcriptional regulation of gene expression through interactions with the 3' untranslated regions (3'UTRs) of target mRNAs (5, 6) . In NSCLC, certain miRNAs have been identified as biomarkers or therapeutic targets; for example, high expression levels of miRNA (miR)-18a, miR-20a and miR-92a correlate with poor prognosis in patients with NSCLC (7) . High expression of miR-493-5p may improve clinical prognosis of NSCLC by targeting the oncogene integrin subunit b1 (8) . miR-410 acts as an oncogene in NSCLC by downregulating solute carrier family 34 member through the activation of the Wnt/β-catenin pathway (9) . However, the functional effects and underlying role of miR-1296 in NSCLC remain unknown. Therefore, the present study investigated the function of miR-1296 in NSCLC.
The results of the present study demonstrated that miR-1296 expression was significantly downregulated in NSCLC tissues and cells. In addition, survival analysis revealed that reduced miR-1296 expression was associated with a poor prognosis in patients with NSCLC. Multivariate Cox analysis demonstrated that reduced miR-1296 expression was an independent risk factor of NSCLC prognosis. Overexpression of miR-1296 inhibited cell proliferation, invasion and Wnt signaling in NSCLC. In conclusion, these results indicated that miR-1296 expression may be a potential biomarker of NSCLC prognosis and potential target of NSCLC treatment. 
Materials and methods

Patients
RNA extraction and reverse transcription-quantitative PCR (RT-qPCR).
Total RNA was extracted from tissues and cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The RNA was reverse transcribed to generate cDNA using Prime Script RT-PCR kit (Takara Biotechnology Co., Ltd.) according to the manufacturer's protocol The thermocycling conditions were as follows: 95˚C for 5 min, followed by 40 cycles of 95˚C for 10 sec and 60˚C for 30 sec. U6 small nuclear RNA was used as an internal control. U6 forward, 5'-CTC GCT TCG GCA GCA CA-3', and reverse, 5'-AAA CGC TTC ACG AAT TTG CGT-3'. miR-1296 primers were purchased from Takara Biotechnology Co., Ltd. The mRNA expression fold changes were calculated using the 2 -ΔΔCq method (11) .
Cell proliferation assay. Cell proliferative ability was evaluated by using Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) according to the manufacturer's instructions. Briefly, transfected cells (3x10 3 cells/well) were seeded in 96-well plates. Following cell were culture for 1, 2, 3 and 4 days, CCK-8 solution was added to each well and then incubated for 2 h at 37˚C in a humidified atmosphere with 5% CO 2 . Cell proliferation was detected by a VICTOR microplate reader (BioTek Instruments, Inc.) and absorbance was measured at 450 nm.
Transwell assay. Transwell cell invasion assay was performed using a 24-well Transwell chamber (Costar; Corning, Inc.) with Matrigel (BD Biosciences). Transfected cells (1x10 5 cells/well) in serum-free medium were seeded in the upper chamber. Medium with 10% FBS was added to the lower chamber. The cells were maintained at 37˚C in a humidified atmosphere with 5% CO 2 for 48 h. The cells in the lower chamber were fixed with 100% methanol for 20 min at 4˚C, stained using 1% crystal violet for 15 min 4˚C and counted using a light microscope (Olympus Corporation).
Western blot analysis. Transfected cells were lysed in radioimmunoprecipitation assay buffer according to the manufacturer's instructions. Protein concentrations were determined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc) by measuring optical density at a wavelength of 280 nm. Protein (30 µg/lane) was separated by SDS-PAGE on 10% gels and transferred onto polyvinylidene fluoride membrane. The membranes were blocked with 5% skimmed milk at room temperature for 1.5 h and incubated with specific primary antibodies against transcription factor 4 (TCF4; 1:1,000; cat. no. sc-8631, Santa Cruz Biotechnology, Inc., CA, USA), β-catenin (1:500; cat. no. sc-16512, Santa Cruz Biotechnology, Inc., CA, USA) and GAPDH (1:1,000; cat. no. sc-16512 2118S, Cell Signaling Technology, Inc., CA, USA) overnight at 4˚C. Primary antibody incubation was followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:1,000; cat. no. sc-2357; Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. The proteins were detected using an enhanced chemiluminescence (ECL) detection system (Bio-Rad Laboratories, Inc.) and an ECL kit (cat. no. 32106; Thermo Fisher Scientific, Inc.). ImageJ software (version 1.48; National Institutes of Health Bethesda) was used to measure the band density. GAPDH was used as a loading control.
Statistical analysis. The data were analyzed using SPSS 18.0 software (SPSS, Inc.). The results are presented as the mean ± standard deviation. Differences between two groups were analyzed using Student's t-test; differences among ≥3 groups were analyzed using one-way analysis of variance, followed by multiple comparisons by the Student-Newman-Keuls test. The χ 2 test was used to evaluate the association between miR-1296 and clinical factors. The Kaplan-Meier method was used to plot the survival curves, and the log-rank test was used for overall survival analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-1296 expression is downregulated in patients with NSCLC and in NSCLC cells.
To analyze the role of miR-1296 expression in NSCLC, the expression levels of miR-1296 in NSCLC tissues and adjacent normal tissues were evaluated by RT-qPCR. The results demonstrated that miR-1296 expression levels in NSCLC tissues were significantly lower compared with in adjacent normal tissues (P<0.05; Fig. 1A ). In addition, four human NSCLC cell lines exhibited significantly downregulated miR-1296 expression compared with the normal control NL20 cell line (Fig. 1B) . Thus, these results indicated that low miR-1296 expression levels may potentially serve as a prognostic marker for patients with NSCLC. Clinicopathological characteristic analysis demonstrated that low miR-1296 expression was closely associated with lymph-node metastasis (P=0.001; Table I ) and advanced TNM stage (P= 0.006; Table I ). By contrast, no association was observed between miR-1296 expression and other clinicopathological features, including sex, age, tumor differentiation and tumor size (Table I) .
Downregulation of miR-1296 expression is associated
Association of miR-1296 expression and prognosis of patients with NSCLC. The Kaplan-Meier method was used to plot the survival curves, which were further analyzed by the log-rank test. The results demonstrated that low miR-1296 expression was associated with poor disease-free survival (DFS; P<0.05; Fig. 2A ) and overall survival (OS; P<0.05; Fig. 2B (Table II) . In addition, lymph node metastasis (P=0.001; HR=1.932; 95% CI, 0.872-3.145), advanced TNM stage (P=0.001; HR=2.063; 95% CI, 0.995-3.448) and low miR-1296 expression (P=0.001; HR=2.138; 95% CI, 1.042-4.349) were independent predictors of poor overall survival rate in NSCLC (Table III) . These results suggested that low miR-1296 expression may be an independent predictor for poor prognosis in patients with NSCLC.
miR-1296 suppresses cell proliferation and invasion in NSCLC cells.
To further investigate the effects of miR-1296 expression in NSCLC cells, CCK-8 cell proliferation and Transwell assays were performed. SK-MES-1 and A549 cells were transfected with a miR-1296 mimic or miR-1296 inhibitor for upregulation or downregulation of miR-1296 expression levels, as they exhibited higher or lower expression of miR-1296 compared with the other two cell lines (Fig. 3A and B) . The results of the CCK-8 assay indicated that miR-1296 overexpression in SK-MES-1 and A549 cells inhibited cell proliferation, whereas reduced miR-1296 expression enhanced cell proliferation compared with respective negative control groups ( Fig. 3C and D) . Additionally, Transwell cell invasion assay demonstrated that miR-1296 overexpression in SK-MES-1 and A549 cells inhibited cell invasive ability, whereas reduced Table II . Univariate and multivariate Cox analysis of disease-free survival in 106 patients with non-small cell lung cancer. miR-1296 expression enhanced cell invasive ability compared with respective negative control groups (Fig. 4) . Thus, these results indicated that miR-1296 may suppress cell proliferation and invasion of NSCLC cells. (Fig. 5) . These results indicated that miR-1296 may suppress Wnt signaling in NSCLC cells.
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Discussion
Abnormal gene expression in cancer involves inactivation of tumor suppressor genes and activation of oncogenes (12) . miRNAs are key regulators of tumor progression in NSCLC, and certain miRNAs are valuable for diagnostics and treatment of NSCLC (13) . A previous study revealed that dysregulation of miRNA expression may be used as sensitive and accurate biomarkers or prognostic predictors of human NSCLC (14) . For example, miR-137 is downregulated and its promoter is hypomethylated in lung cancer, and high levels of miR-137 promoter methylation are associated with poor disease-free survival in NSCLC (15) ; plasma exosomal microRNA-451a is a noninvasive biomarker for early prediction of recurrence and prognosis in non-small cell lung cancer (NSCLC) patients after curative resection (16) . Serum miR-494 was significantly elevated in NSCLC patients and closely correlated with poor clinical outcome (17) .
miR-1296 has been identified as a tumor suppressor in several types of cancer; for example, miR-1296-5p may be involved in the regulation of migration and invasion of human gastric cancer cells at least in part by targeting the erb-b2 receptor tyrosine kinase 2 (ERBB2)/Rac family small GTPase 1 signaling pathway (18) . miR-1296-5p is involved in the regulation of proliferation of breast cancer cells by targeting the ERBB2/MTOR complex 1 signaling pathway (19) . Downregulation of miR-1296 may serve as a prognostic biomarker in hepatocellular carcinoma (HCC) and miR-1296 inhibits metastasis and epithelial-mesenchymal transition in HCC by targeting the SRSF protein kinase 1-mediated PI3K/AKT pathway (20) . In the present study, miR-1296 expression was significantly downregulated in NSCLC tissues compared to adjacent normal tissues. In addition, miR-1296 expression was downregulated in NSCLC cell lines compared with a normal lung cell line. Survival analysis demonstrated that low miR-1296 expression predicted poor prognosis. Additionally, multivariate Cox analysis revealed that low miR-1296 expression was an independent risk factor of NSCLC prognosis. Thus, these results indicated that miR-1296 expression level may be a potential biomarker for NSCLC prognosis.
The present study demonstrated that miR-1296 overexpression inhibits cell proliferation and invasion, whereas reduced miR-1296 expression enhanced cell proliferation and invasion compared with the control groups. Wnt signaling pathway is involved in tumor cell proliferation and invasion in NSCLC (21) ; in the present study, miR-1296 overexpression inhibited Wnt signaling by reducing the expression levels of two key proteins, β-catenin and TCF4, in NSCLC cells. By contrast, downregulation of miR-1296 significantly promoted Wnt signaling by increasing β-catenin and TCF4 expression in NSCLC cells.
In conclusion, the present study demonstrated that miR-1296 expression was reduced in NSCLC tissues and cell lines compared with healthy tissues and cells. In addition, low miR-1296 expression was associated with advanced TNM stage and lymph-node metastasis of patients with NSCLC. miR-1296 expression level was identified as a prognostic predictor of NSCLC. Overexpression of miR-1296 inhibited cell proliferation, invasion and Wnt signaling in NSCLC. These results indicated that miR-1296 expression may be a potential biomarker for NSCLC prognosis, as well as a potential target of NSCLC treatment.
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